What to watch with CYP2C19 and gut health?

CYP2C19 is a cytochrome P450 enzyme that metabolizes many drugs, including proton pump inhibitors (PPIs) like omeprazole, which are commonly used for acid reflux and gastritis. Genetic variants (e.g., *2, *3) result in poor, intermediate, extensive, or ultrarapid metabolizer phenotypes. In poor metabolizers, PPIs can achieve higher efficacy but also increase the risk of side effects such as small intestinal bacterial overgrowth (SIBO) or nutrient deficiencies (magnesium, vitamin B12). Additionally, the gut microbiome may modulate CYP2C19 activity, creating a bidirectional interaction. However, direct evidence linking CYP2C19 variants to gut health outcomes is limited and mixed. Genetic testing can guide PPI dosing but should not be used as a standalone gut health assessment. Always consult a doctor before adjusting medication. Caveat: CYP2C19 is primarily a drug-metabolism gene, not a gut health marker.